ALLA IOSPA: Open Payments
NPI 1710058896 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,942 in 64 payments from 13 companies in 2025. Trend: 2023 $476 · 2024 $699 · 2025 $1,942
Food & beverage: $1,843Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $383 |
| Axsome Therapeutics, Inc. | 8 | $351 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $335 |
| Otsuka America Pharmaceutical, Inc. | 10 | $242 |
| Teva Pharmaceuticals USA, Inc. | 4 | $155 |
| Alkermes, Inc. | 7 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Vanda Pharmaceuticals Inc. | 2 | $68 |
| Supernus Pharmaceuticals, Inc. | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 1 | $37 |
Products named: VRAYLAR, Auvelity, CAPLYTA, REXULTI, TRINTELLIX, LYBALVI, FANAPT, ARISTADA.
Industry payments across NY — which companies pay providers there.
